SCHEMBL6322736

SCHEMBL6322736

CC(=O)N(CCCN)c1ccc(NC(=C2C(=O)Nc3ccccc32)c2ccccc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2C P18825 1/20 0.41
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
IDO1 P14902 2/20 0.36
TDO2 P48775 1/20 0.36
KDR P35968 1/20 0.36
ALDH1A1 P00352 2/20 0.34
ADRB2 P07550 1/20 0.34
CFTR P13569 2/20 0.34
HPGD P15428 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
AKT2 P31751 2/20 0.33
CA12 O43570 2/20 0.33
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
CA9 Q16790 2/20 0.33
PDPK1 O15530 1/20 0.33
AKT1 P31749 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6322733 1.00 ADRA2C (0.41) ADRA2CMEN1NPC1RAB9AKMT2A
SCHEMBL6320087 0.91 ADRA2C (0.40) ADRA2CMEN1NPC1RAB9AKMT2A
SCHEMBL6320093 0.91 ADRA2C (0.40) ADRA2CMEN1NPC1RAB9AKMT2A
SCHEMBL6319632 0.91 MEN1 (0.38) MEN1NPC1RAB9AKMT2AIDO1
SCHEMBL6319638 0.91 MEN1 (0.38) MEN1NPC1RAB9AKMT2AIDO1
SCHEMBL6328162 0.90 MEN1 (0.37) MEN1NPC1RAB9AKMT2AIDO1
SCHEMBL6325597 0.90 MEN1 (0.37) MEN1NPC1RAB9AKMT2AIDO1
SCHEMBL4504209 0.89 ADRA2C (0.38) ADRA2CIDO1TDO2KDRCFTR
SCHEMBL4504212 0.89 ADRA2C (0.38) ADRA2CIDO1TDO2KDRCFTR
SCHEMBL6319359 0.89 MEN1 (0.39) MEN1NPC1RAB9AKMT2AIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6855710-B2 Substituted indolines with an inhibitory effect on various kinases and complexes of CDKs BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-02-15 US disclosed
US-20040058978-A1 Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-03-25 US disclosed
EP-1115704-B1 NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES BOEHRINGER INGELHEIM PHARMA (DE) 2003-06-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058978-A1 Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs CDK1, CDK2, CDK3 ADRA2C 1686/4885MEN1 3345/4885NPC1 4477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.